
Edwards Lifesciences Corp guidance
$107.11−0.04%Close 16 Nov 2026 · Market value $61.54B
In its results release of 4 Nov 2026 (Q3 FY2026), Edwards Lifesciences Corp gave 1 forecast in figures, among them revenue of $1.67B to $1.75B for Q4 FY2026. Over the last two years, results landed above the company's own last range 6 of 12 times, within it 6 and below it 0.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q3 FY2026 results, 4 Nov 2026
| Measure | Period | Guidance | As stated |
|---|
| Revenue | Q4 FY2026 | $1.67B to $1.75B | For the fourth quarter of 2026, the company projects total sales to be between $1.67 and $1.75 billion and adjusted EPS of $0.61 to $0.69. |
|---|
Source: the company's earnings release.
Guidance against results above 6 · within 6 · below 0
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Organic revenue growth | FY2026 | +10% to +11% | Given once | — | To come |
|---|
| EPS · Adjusted | FY2026 | $2.95 to $3.05 | Given once | — | To come |
|---|
| EPS growth · Adjusted | FY2026 | +17% | Given once | — | To come |
|---|
| Revenue | FY2026 | $6.60B to $6.90B | Raised once | — | To come |
|---|
| Organic revenue growth | FY2026 | +9% to +11% | Given once | — | To come |
|---|
| EPS · Adjusted | FY2026 | $2.95 to $3.05 | Raised once | — | To come |
|---|
| EPS | FY2026 | $2.90 to $3.05 | Given once | — | To come |
|---|
| Gross margin · Adjusted | FY2026 | 78% to 79% | Given once | — | To come |
|---|
| Revenue | Q4 FY2026 | $1.67B to $1.75B | Given once | — | To come |
|---|
| Revenue | Q2 FY2026 | $1.66B to $1.74B | Given once | $1.74B | Within the range |
|---|
| EPS · Adjusted | Q2 FY2026 | $0.70 to $0.76 | Given once | $0.78 | Above the range |
|---|
| Revenue | Q1 FY2026 | $1.55B to $1.63B | Given once | $1.65B | Above the range |
|---|
| EPS · Adjusted | Q1 FY2026 | $0.70 to $0.76 | Given once | $0.78 | Above the range |
|---|
| Revenue | FY2025 | $5.90B to $6.10B | Raised once | $6.07B | Within the range |
|---|
| Revenue growth | FY2026 | +9% to +10% | Unchanged | +11.55% | Above the range |
|---|
| Revenue | Q4 FY2025 | $1.51B to $1.59B | Given once | $1.57B | Within the range |
|---|
| EPS · Adjusted | Q4 FY2025 | $0.58 to $0.64 | Given once | $0.58 | Within the range |
|---|
| Revenue | Q3 FY2026 | $1.46B to $1.54B | Given once | $1.55B | Above the range |
|---|
| EPS · Adjusted | Q3 FY2026 | $0.54 to $0.60 | Given once | $0.67 | Above the range |
|---|
| Revenue | Q2 FY2025 | $1.45B to $1.53B | Given once | $1.53B | Above the range |
|---|
| Revenue | Q1 FY2025 | $1.35B to $1.43B | Given once | $1.41B | Within the range |
|---|
| Revenue | Q4 FY2024 | $1.33B to $1.39B | Given once | $1.39B | Within the range |
|---|
EW in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.